Lucrin Depot 11,25 Mg Pds 11,25 mg Lyophilised microspheres and sterile diluent for suspension for injection
PDF Leaflet Revision Date: 20 October 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Palliative treatment of advanced prostatic cancer, endometriosis, uterine fibroids, and as adjuvant therapy in breast cancer.
Dosage (summary)
11.25 mg subcutaneous or intramuscular injection every 3 months.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- Concomitant use with QT prolonging drugs
- Bupropion
- SSRIs
Contraindications
- Hypersensitivity to leuprolide acetate
- Pregnancy
- Breastfeeding
- Undiagnosed vaginal bleeding
Common side effects
- Hot flushes
- Weight gain
- Erectile dysfunction
- Fatigue
- Bone pain
Counselling Points
- Monitor blood glucose
- Use non-hormonal contraception if needed
- Report any severe side effects immediately
Serious warnings
- Risk of anaphylaxis
- Potential for convulsions
- Flare effect in prostate cancer
Important Disclaimer
The Lucrin Depot 11,25 Mg Pds 11,25 mg Lyophilised microspheres and sterile diluent for suspension for injection professional information leaflet below is the property of AbbVie and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
